Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Do you even know what immunotherapy is?
Tapimmune will soar in 2014 no matter what. Market maker manipulation, bashing - nothing will keep
this great science from achieving its destiny. Our first human trial data is stellar. You can tell early on that this company is going to be an immunotherapy leader.
Lately I've seen some biotechs like Marina Biotech, Benitec and Arrowhead Research stay above their capital raise prices and continue to move higher with no movement toward the capital raise share price. This hungry environment for development biotechs has changed the old rules where a capital raise would bring the price down to that level. Especially since these results don't incorporate the new class I Mayo antigen.
Huge news that met management's highest expectations.
Stock should be at $10 based on this excellent news today. It's a bad day for the market, but I think we may still
Close near $5 or higher by 4pm.
Yes I agree. It will be interesting to see Big Pharmas approach Tapimmune once we get some clinical data published. I hope we become the Seattle Genetics of cancer and infectious disease vaccines, holding key technology patents that others absolutely need to take a license to.
The R/S is successful because they have great science and significant competitive advantages with PolyStart, the original TAP technology and the access to the Mayo antigens through the collaboration with Keith Knutson. Our relationship with Keith is a huge advantage for the future. The combination of all of these unique assets makes us special and sought after.
A capital raise in my opinion will actually propel the price even higher as we go over $5 per share, more blue chip, life science institutional investors will want to pile in. The time is right for immunotherapy companies and the apetite for revolutionary biotech investments is strong.
Nice to read in the shareholder letter that PolyStart could become a
platform that creates many revenue generation opportunities.
The Mayo class I antigen for HER2/neu mentioned in the letter is a real game changer since no other company has access to it. Go back to the April 16, 2012 press release to read why it is so special. Basically it is naturally occurring. That class I antigen, the class II antigens, TAP and PolyStart make an unrivaled combination that should become the gold standard for HER2/neu cancers in my opinion.
Sounds like many positive catalysts are anticipated in 2014. Wilson did a great job in the shareholder letter today explaining just how powerful our technical advantage is and how we intend to finally monetize that advantage. PolyStart is even more important than I thought. Huge competitive advantage. Although small volume, the stock price continues its upward march.
I believe the current TPIV price reflects known risk of potential dilution. It's been public knowledge for 2 months. I believe if holders of TPIV debt are willing to take TPIV preferred which converts to common shares as repayment, that is a bullish sign for us. These creditors know more about TapImmune's prospects than we do. The TPIV pps trend is up since mid December. The current market cap is $3.8 million. A competitor, Inovio is valued at $671 million! Even if mgmt increases common TPIV shares outstanding by 500%, our market cap would still only be $20 million! A long way from $671 million! A capital raise would increase institutional confidence in TPIV and send the price even higher!
Look at ARWR once institutions supported the stock. Up 1000% since their first capital raise less than a year ago. Capital raises show confidence in the company and propel the stock higher. TPIV has more going for it technically than ARWR. The RS and a capital raise will do the same for TPIV because we have great science! Institutions know that!
Does anyone think they are sitting on good news and hoping to announce it after the RS changes the stock price? Won't be as much of a penny stock if the price was $2.60 today. Over $5 and big institutions would be allowed to buy in. I think we are on the verge of good things happening. TAP plus the Mayo antigens is a game changer! Bet institutions are just waiting to buy in when they can.
Google " Glynn Wilson Tapimmune YouTube" and watch the Apr 26 2012 recording and listen to why he believes Tapimmune's technology with the new antigen no other company had access to will produce a superior solution for many HER2/neu breast cancer patients. I think Knutson also believes it has strong potential in ovarian cancer too.
I am hoping they have some good news flow to keep the price moving up to entice more institutional investors to pile in. Hopefully they will finally achieve milestones they have been talking about for years.
I am hoping they have some good news flow to keep the price moving up to entice more institutional investors to pile in. Hopefully they will finally achieve milestones they have been talking about for years.
Google "YouTube Tapimmune Keith Knutson" and listen to an interview that explains the advantages of Tapimmune's technology. Also scroll down to see other interviews with Glynn Wilson our CEO. He explains our advantages very clearly.
You should read about why TPIV has a superior vaccine to Other approaches for HER2-neu. Glynn Wilson explains it well on the Tapimmune website. If Galena is valued at $438 million, Tapimmune will be valued at double that value when we get to Phase 3 testing.
Centra Holdings is also a large institutional shareholder with over 13 million TPIV shares. Tonaquint and Centra will put pressure on Management to increase shareholder value more quickly. That's a good thing. What is your individual interest in Tapimmune? Are you a shareholder or thinking about investing in TPIV? You obviously spend time following the company.
Hopefully the large institutions like Tonaquint that own our debt (hopefully converted to preferred shares) will also participate in a capital raise after the RS. Speculation on my part but it is what we need to restart the engine. Our management is converting their preferred shares to common at the time of the RS. Probably to free up the 5 million preferred shares authorized in our capital structure for the holders (Tonaquint and others) of our debt. We need a clean balance sheet for the capital raise to occur. Management probably has a plan for maintaining momentum and interest in TPIV after the RS. They want the stock to go up too since they will own a lot of it on Feb. 17! Speculation on my part but I have seen this scenario play out at other biotechs. Don't mistake their lack of news since early Oct for a lack of activity. Many things have probably been going on behind the scenes.
Institutional support for TPIV after the RS is key. If they jump in and accumulate the stock because they see good news stories showing new developments, the price will go up. That should be the goal of our management. Institutions will bid it up and create the snowball effect to get TPIV to a price that reflects its potential. Then the next capital raise will be at a higher price and the stock will continue to climb as they progress through Phase 1.
TPIV will soar with positive Phase 1 results. Stock price can climb as they raise more cash leading to Phase 2. Then positive Phase 2 results provide huge value creation. By the time it is in Phase 3 patient investors will have already made a fortune. Look at Alnylam and Arrowhead for how a company can increase the share price with capital raises. Great science always finds new investors once data confirms the approach has strong potential. Don't have to wait until FDA approval to get rich.
Positive news stories after the RS would help to support the stock price. Hopefully we see some positive developments after the RS.
After the RS Tapimmune will not be a penny stock as it will be at $2 or higher if the price stays at current levels or drifts higher. Arrowhead started their run at around $2 when the capital raises started lifting their stock price higher and higher.
I am glad Koos is still paying himself in ENTB shares! His interests are aligned with ours as he will
Do his best to increase the ENTB stock price and make us and himself rich! But he has a long term view and will forego short term gains to maximize the long term value of the company. Just hold your ENTB shares and give Koos time to accomplish the vision.
I think TPIV stock could drift higher over the next two weeks in anticipation of the RS. Although converting the $5 million in debt on our books to common shares would dilute percent ownership, it would also create a much healthier balance sheet and eliminate investor uncertainty. It could cause a stock price increase. Look at how our stock price rose after June 29, 2009 when Wilson took over and they converted $3.2 million in debt to equity. The stock price rose! Capital raises also will dilute percent ownership but they can actually cause a stock price increase because they eliminate uncertainty and increase investor confidence when institutions buy in and show confidence in the company. Look at Arrowhead Research (ARWR) in the RNAi space and how the stock price rose after they issued more shares in capital raises in 2013! Having the cash to complete trials is key to Tapimmune experiencing significant value creation.
The latest 14c says on or about Feb. 17. They are trying to convert the $5 million debt to equity as well.
The latest 14c says on or about Feb. 17. They are trying to convert the $5 million debt to equity as well.
I don't think Wilson and other insiders would convert their preferred shares to common shares at the time of the RS if they expected their price to decline after the RS. Don't you think insiders expect the price to rise soon?
Wow, feels like price manipulation downward! Who would sell at these prices with all the potential and the fact that insiders are getting ready to convert their preferred shares to common shares. Anyone care to comment?
Wow, feels like price manipulation downward! Who would sell at these prices with all the potential and the fact that insiders are getting ready to convert their preferred shares to common shares. Anyone care to comment?
Upward pressure on price on a bad day for the market is a good sign.
Impressive list of competitive advantages from a PR when Tapimmune was GeneMax Corp on Sept. 9, 2003. Just shows how long it takes these biotechs to get the stars aligned but I think TPIV is getting ready to roll:
Based on cancer incidence data collected for the year 2000 from a Lyon, IARCPress document of 2001, the Company's TAP cancer technology, if successful, may form a relevant immunotherapy for 60%-70% of all new incidences of cancer in the US, Japan, and the four major European markets. The competitive advantages include: efficacy against secondary cancerous growths elsewhere in the body, no restrictions on the patient's HLA type, no restrictions regarding the genetics of the tumors, and non-toxicity to normal cells. The technology is complementary and synergistic with all other immunotherapies dependent on cytotoxic T cell killing and also has the potential to enable a variety of tumor antigen vaccines.
Dilution may not occur at all after the reverse split! On May 24, 2010, Tapimmune sold $1.5 million in Secured Convertible Notes. They were issued with warrants to buy common shares but I don't think they created dilution the day they received the $1.5 million from investors. If they play it right, they do the reverse split, issue some great news to get the price up over $5 and then secure only the funding needed through a debt offering to complete some trials. Maybe the future exercise price is over $5! Remember, when the reverse split takes place Wilson and the senior leadership team get their preferred shares converted to common shares. Wouldn't you do that if you thought the price of the common shares had a really good chance of rising?
Mayo Clinic contacted Tapimmune to work with them! Google "Tapimmune evoking aggressive response by the immune system" It's an article written by ME Garza on Apr. 6, 2011 and provides excellent background info on the collaboration between the two entities. A must read.
Dr. Wilson, issue a stock dividend to all common holders to force identification of naked short sellers! Let's eliminate their value destroying game that ultimately harms patients who could benefit from faster commercialization of our groundbreaking vaccines!
Great! glad we will be done with them!
David Koos, please find a way to identify all naked short sellers and prevent them from harming the patients that could be helped by BMSN's drugs. Hope they never get the diseases we could be curing if the stock could rebound to its fair price.
Google "Entest COPD Patents" and "Entest May 13 2010" and "Entest May 11 2010"
to learn more about Entest. Naked short sellers have harmed patients with COPD by shorting this stock over the years. In the end this stock will soar because you can't keep good science down! Short sellers will lose as they deserve to!
Dear Management please find non-dilutive sources of funds so we can avoid any equity capital raises. After conversion of your preferred shares to common shares, your interests will be even more aligned with ours. Don't dilute yourselves! Let's get the stock price back up to 25 cents where it was briefly in April
2012.
Find the David Koos videos on YouTube from 2010 or so where he discusses his innovative ideas for treating COPD. They have 3 patents. This is why I invested in Entest Biomedical. David Koos has donated his own money to the company and wants to see the stock price soar since he owns tens of millions of shares! He is very visionary and will win with this company in time. Buy shares and set them aside for 10 years and see what happens!